|Dr. Andre Choulika Ph.D.||Co-Founder, CEO & Director||879.06k||N/A||1965|
|Dr. David J. D. Sourdive Ph.D.||Director, Deputy CEO, Exec. VP of CMC and Manufacturing||580.28k||N/A||1967|
|Dr. Bing C. Wang M.B.A., Ph.D.||Chief Financial Officer||N/A||N/A||1977|
|Valerie Cros||Principal Financial Officer & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. Jean Charles Epinat||Chief Technological Officer||N/A||N/A||N/A|
|Dr. Philippe Duchateau Ph.D.||Chief Scientific Officer||N/A||N/A||1963|
|Mr. Stephan Reynier M.Sc., MSc||Chief Regulatory & Pharmaceutical Compliance Officer||N/A||N/A||1969|
|Ms. Marie-Bleuenn Terrier||Gen. Counsel & Sec. of the Board of Directors||N/A||N/A||1982|
|Pascalyne Wilson||Director of Communications||N/A||N/A||N/A|
|Ms. Kyung Nam-Wortman||Exec. VP & Chief HR Officer||N/A||N/A||1970|
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A.’s ISS governance QualityScore as of 1 October 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 8.